105 related articles for article (PubMed ID: 37137530)
1. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F; Visentin A; Schirinzi E; Salvalaggio A; Cacciavillani M; Candiotto C; Baratè C; Cellini A; Bertorelle R; Siciliano G; Trentin L; Briani C
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37137530
[TBL] [Abstract][Full Text] [Related]
2. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88
Guérémy A; Boucraut J; Boudjarane J; Grapperon AM; Fortanier E; Farnault L; Gabert J; Vely F; Lacroix R; Kouton L; Attarian S; Delmont E
J Neurol; 2024 Mar; 271(3):1320-1330. PubMed ID: 37979093
[TBL] [Abstract][Full Text] [Related]
3. Anti-myelin-associated glycoprotein neuropathy: Where do we stand?
Stino AM; Elsheikh B; Allen JA
Muscle Nerve; 2023 Nov; 68(6):823-832. PubMed ID: 37602932
[TBL] [Abstract][Full Text] [Related]
4. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].
Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969
[TBL] [Abstract][Full Text] [Related]
5. Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.
Pertesi M; Galia P; Nazaret N; Vallée M; Garderet L; Leleu X; Avet-Loiseau H; Foll M; Byrnes G; Lachuer J; McKay JD; Dumontet C
PLoS One; 2015; 10(9):e0136505. PubMed ID: 26352266
[TBL] [Abstract][Full Text] [Related]
6. [Anti-Myelin-associated Glycoprotein Neuropathy].
Kuwahara M
Brain Nerve; 2024 May; 76(5):540-546. PubMed ID: 38741494
[TBL] [Abstract][Full Text] [Related]
7. Current approach to Waldenström macroglobulinemia.
Kapoor P; Rajkumar SV
Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
[TBL] [Abstract][Full Text] [Related]
8. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
[TBL] [Abstract][Full Text] [Related]
9. Paraproteinemic Neuropathies.
Beydoun SR; Darki L
Continuum (Minneap Minn); 2023 Oct; 29(5):1492-1513. PubMed ID: 37851040
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients.
Aotsuka Y; Misawa S; Suichi T; Shibuya K; Nakamura K; Kano H; Otani R; Morooka M; Ogushi M; Nagashima K; Sato Y; Kuriyama N; Kuwabara S
Eur J Neurol; 2024 May; 31(5):e16249. PubMed ID: 38375741
[TBL] [Abstract][Full Text] [Related]
11. New developments in the diagnosis and characterization of Waldenström's macroglobulinemia.
García-Sanz R; Hunter ZR; Poulain S; Varettoni M; Owen RG
Expert Rev Hematol; 2023; 16(11):835-847. PubMed ID: 37905549
[TBL] [Abstract][Full Text] [Related]
12. Time course of the autoantibody response to therapy in anti-MAG neuropathy: TWO case REPORTS.
Cornejo AC; Latov N
Heliyon; 2024 Apr; 10(7):e28870. PubMed ID: 38601656
[TBL] [Abstract][Full Text] [Related]
13. Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib.
Naveed Ahmad JA; Schroeder BA; Yun JPT; Aboulafia DM
Case Rep Oncol; 2023; 16(1):1353-1361. PubMed ID: 37946745
[TBL] [Abstract][Full Text] [Related]
14. TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience.
Chompoopong P; Rezk M; Mirman I; Berini SE; Dyck PJB; Mauermann M; Shouman K; Klein C; Mills JR; Dubey D
J Neurol; 2023 Sep; 270(9):4523-4528. PubMed ID: 37294321
[TBL] [Abstract][Full Text] [Related]
15. A novel cell-based immunofluorescence assay for the detection of autoantibodies to myelin-associated glycoprotein.
Mariotto S; de Gaspari P; Jäger D; Hahn S; Forni C; Saschenbrecker S; Lattwein E; Dinoto A; Ferrari S
Front Neurol; 2023; 14():1289810. PubMed ID: 38169815
[TBL] [Abstract][Full Text] [Related]
16. Waldenstrom's Macroglobulinemia: An Update.
Mazzucchelli M; Frustaci AM; Deodato M; Cairoli R; Tedeschi A
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018004. PubMed ID: 29326801
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.
Liu B; Hu J; Sun C; Qiao K; Xi J; Zheng Y; Sun J; Luo S; Zhao Y; Lu J; Lin J; Zhao C
J Neurol; 2023 Sep; 270(9):4288-4295. PubMed ID: 37195346
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.
Pratt G; El-Sharkawi D; Kothari J; D'Sa S; Auer R; McCarthy H; Krishna R; Miles O; Kyriakou C; Owen R
Br J Haematol; 2022 Apr; 197(2):171-187. PubMed ID: 35020191
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy: A Multicenter Cohort Study in South Korea.
Min YG; Han HJ; Shin HY; Baek JG; Kim JS; Park KS; Baek SH; Yoo I; Huh SY; Kwon YN; Choi SJ; Kim SM; Hong YH; Sung JJ
J Clin Neurol; 2024 Jan; 20(1):50-58. PubMed ID: 38179632
[TBL] [Abstract][Full Text] [Related]
20. How I treat rituximab refractory patients with WM.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA
Oncotarget; 2018 Dec; 9(96):36824-36825. PubMed ID: 30627320
[No Abstract] [Full Text] [Related]
[Next] [New Search]
